Relevant bibliographies by topics / Early heart failure

Academic literature on the topic 'Early heart failure'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Early heart failure.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Early heart failure"

1

Creager, Mark A. "Early Intervention in Heart Failure." Drugs 39, Supplement 4 (1990): 4–9. http://dx.doi.org/10.2165/00003495-199000394-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Spacie, Robin, James M. Duffell, and Megan Jones. "Heart failure." InnovAiT: Education and inspiration for general practice 12, no. 5 (March 25, 2019): 243–51. http://dx.doi.org/10.1177/1755738019829789.

Full text
Abstract:
Heart failure is a progressive condition that is increasing in prevalence. Clinical findings, together with natriuretic peptide measurement and echocardiography, underpin diagnosis. Drugs can improve the prognosis (ACE-inhibitor, beta blockers) and ameliorate symptoms (diuretics). Non-pharmacological treatment includes exercise therapy, smoking cessation and nutritional care. Heart failure has a poor prognosis and early palliative input is recommended.
APA, Harvard, Vancouver, ISO, and other styles
3

Gustafsson, I., and P. Hildebrandt. "Early Failure of the Diabetic Heart." Diabetes Care 24, no. 1 (January 1, 2001): 3–4. http://dx.doi.org/10.2337/diacare.24.1.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Subramaniam, Kathirvel. "Early Graft Failure After Heart Transplantation." International Anesthesiology Clinics 50, no. 3 (2012): 202–27. http://dx.doi.org/10.1097/aia.0b013e3182603ead.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

ERIKSSON, HENRY, KURT SVÄRDSUDD, KENNETH CAIDAHL, THORVALD BJURÖy, BO LARSSON, LENNART WELIN, LARS-OLOF OHLSON, and LARS WILHELMSEN. "Early Heart Failure in the Population." Acta Medica Scandinavica 223, no. 3 (April 24, 2009): 197–209. http://dx.doi.org/10.1111/j.0954-6820.1988.tb15788.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Peacock, William Frank, Charles Emerman, Maria R. Costanzo, Deborah B. Diercks, Margarita Lopatin, and Gregg C. Fonarow. "Early Vasoactive Drugs Improve Heart Failure Outcomes." Congestive Heart Failure 15, no. 6 (November 2009): 256–64. http://dx.doi.org/10.1111/j.1751-7133.2009.00112.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kotooka, Norihiko. "Biomarkers for Early Diagnosis of Heart Failure." Journal of Cardiac Failure 18, no. 10 (October 2012): S137. http://dx.doi.org/10.1016/j.cardfail.2012.08.079.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kwak, Min Ji, Lincy S. Lal, John M. Swint, Xianglin L. Du, Wenyaw Chan, Bindu Akkanti, and Abhijeet Dhoble. "Early tracheostomy in acute heart failure exacerbation." Heart & Lung 49, no. 5 (September 2020): 646–50. http://dx.doi.org/10.1016/j.hrtlng.2020.03.024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Xiaoxia, Chun Song, Xiao Zhou, Xiaorui Han, Jun Li, Zengwu Wang, Haibao Shang, Yuli Liu, and Huiqing Cao. "Mitochondria Associated MicroRNA Expression Profiling of Heart Failure." BioMed Research International 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/4042509.

Full text
Abstract:
Heart failure (HF) is associated with mitochondrial dysfunction and energy metabolism impairment. MicroRNAs are implicated in the development of heart failure. However, the mitochondria enriched microRNA during heart failure remains elusive. Here, we generated a pressure overload-induced early and late stage heart failure model at 4 weeks and 8 weeks following transverse aortic constriction (TAC) in mice. We found that expression of mitochondrion protein COX4 was highly enriched in isolated mitochondria from cardiac tissues while GAPDH could hardly be detected. Furthermore, small RNA sequencing for mitochondria RNAs from failing hearts was performed. It was found that 69 microRNAs were upregulated and 2 were downregulated in early heart failure, while 16 microRNAs were upregulated and 6 were downregulated in late heart failure. 15 microRNA candidates were measured in both mitochondria and total cardiac tissues of heart failure by real-time PCR. MiR-696, miR-532, miR-690, and miR-345-3p were enriched in mitochondria from the failing heart at early stage. Bioinformatics analysis showed that mitochondria enriched microRNAs in HF were associated with energy metabolism and oxidative stress pathway. For the first time, we demonstrated microRNAs were enriched in mitochondria during heart failure, which established a link between microRNA and mitochondrion in heart failure.
APA, Harvard, Vancouver, ISO, and other styles
10

Yontz, Lynn L. "Congestive Heart Failure: Early Recognition of Congestive Heart Failure in the Primary Care Setting." Journal of the American Academy of Nurse Practitioners 6, no. 6 (June 1994): 273–79. http://dx.doi.org/10.1111/j.1745-7599.1994.tb00952.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Early heart failure"

1

Bartone, Cheryl L. "Variables that increase heart failure patients' risk of early readmission: a retrospective analysis." University of Cincinnati / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1377869498.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Su, Joseph C. C. 1977. "Developing an early warning system for congestive heart failure during a Bayesian reasoning network." Thesis, Massachusetts Institute of Technology, 2001. http://hdl.handle.net/1721.1/89329.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Savage, Henry Oluwasefunmi. "Early detection of decompensation of chronic heart failure using a non-contact monitor of nocturnal respiratory patterns." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/24577.

Full text
Abstract:
Heart failure affects 1-2% of the adult population in the United Kingdom and accounts for the majority of hospitalisations in patients with cardiovascular disease. The financial implications are enormous as it consumes 1-2% of the national health care budget with 70% of these costs relating to hospitalisation expenses. Prevention of these admissions may be possible by detecting early signs of decompensation in patients with chronic heart failure (CHF) and instituting interventions that may steer the course of disease back to stability without the need for a hospital inpatient stay. Further, Sleep Disordered Breathing (SDB) and in particular Central Sleep Apnoea (CSA) is found in patients with CHF and at any symptomatic stage of the condition. This may be associated with Cheyne-Stokes Respiration (CSR), which has been shown to be an independent predictor of mortality. In the first study of this thesis, I investigated the accuracy of the SleepMinderTM (SM) device; which is a non-contact monitor of nocturnal respiratory patterns; in diagnosing SDB by deriving measures of the Apnoea Hypopnea Index (AHI) and percentage overnight CSR from the SM signals. I found that SM was good in terms of diagnostic accuracy with an area under receiver operator characteristic curve (ROC) of 0.82 (p=0.02) for an AHI threshold >15, but only moderately so for % overnight CSR>0, with an area under ROC curve of 0.72 (p=0.06). In the second study, I examined the changes that occur in SM derived respiratory parameters over a long period of monitoring and found that the AHI, quantity of CSR, Total Sleep Time (TST) and Respiratory Rate (RR) were highly variable with Intra-Class Correlation (ICC) measures of 0.32, 0.39, 0.25, 0.36 respectively over a period of 12 months. Relying on data from a year rather than a single night resulted in misclassification of patients into a different severity group of SDB during 35% of the follow up period and placed patients into a different treatment group during 21% of this period. I also observed that a high proportion (59%) of patients studied had a mean AHI that was consistently above the accepted threshold for treatment (AHI>15). This was consistent even over a shorter follow up period of 2 weeks suggesting that a single night measure of the AHI may not be a sufficient risk assessment of SDB in heart failure patients. In the final study, I have investigated the predictive value of the SleepMinderTM for acute decompensation of heart failure (ADHF) using algorithms derived from its signals. I found that the SM was not accurate for this purpose, performing with a sensitivity and specificity of 0.38 and 0.71, respectively. In summary this study has demonstrated that the SleepMinderTM device provides a novel screening method, which is convenient for the detection of sleep disordered breathing in patients with CHF. It performs with a good diagnostic accuracy and is acceptable to these patients due to its non-contact operation. Algorithms derived from its signals however cannot be used to predict acute decompensation of chronic heart failure. Further, longitudinal analyses of nocturnal respiratory patterns in these patients have demonstrated that the Apnoea Hypopnea Index (AHI) is highly variable over a prolonged period of monitoring and a mean value rather that a single night measurement may be a more appropriate risk assessment tool for SDB. This requires confirmation.
APA, Harvard, Vancouver, ISO, and other styles
4

Boyd, Kirsty Jean. "Early palliative care for people with advanced illnesses : research into practice." Thesis, University of Edinburgh, 2016. http://hdl.handle.net/1842/23389.

Full text
Abstract:
Identifying people with advanced illnesses whose health is deteriorating, assessing their needs and planning care proactively with them are healthcare priorities given the demographic trend of ageing populations in the UK and internationally. Over the past 10 years (2004-2014), I have led a series of research studies that have made an important academic contribution to improving palliative care services for patients with heart disease and advanced multimorbidity. My first paper reported secondary analysis of data generated from a qualitative study of the illness and care experiences of patients with advanced heart failure. This work used innovative, qualitative research methods to explore and understand patient, carer and health professional perspectives over time. My second study then evaluated whether health and social care services were configured and delivered in response to the needs of people with heart failure and their families. This led me to recommend an anticipatory care framework which integrated a palliative care approach with other aspects of treatment and care. Around this time, advance care planning (planning ahead to facilitate end-of-life care aligned with people’s goals and preferences) was being strongly advocated by NHS health policy makers despite limited research in the UK. For my third study, I evaluated an evidence-based, educational intervention for general practitioners while also exploring barriers and facilitators to advance care planning in primary care for patients with cancer or other advanced conditions. It was becoming increasingly clear that failure to identify people with deteriorating health and a high risk of dying in a timely way was a major barrier to more effective palliative care. The problem was greatest for patients with non-malignant conditions whose illness trajectory is much less easy to predict than in cancer populations. I therefore started to research and develop a new clinical tool designed to prompt early, proactive patient identification in routine clinical practice – the Supportive and Palliative Care Indicators Tool (SPICT). My fourth research paper reported an evaluation of the SPICT in a mixed-methods study in a large tertiary care hospital. The SPICT was then used to identify people with multimorbidity for my fifth study, a longitudinal exploration of patient and carer experiences of hospital admission and ongoing community care. In my final paper, I drew on my previous research and combined this with well-developed approaches to timely identification and effective communication. I described the design of a successful pilot randomised trial of future care planning with people who had advanced heart disease and their carers. This thesis presents a critical review of these six research studies setting them in context and demonstrating the impact they have had in ensuring that high quality research evidence informs current and future developments in palliative care policy and clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
5

Lewis, Peter Andrew. "Identification of early cardiac decompensation and the management of intraaortic balloon counterpulsation weaning." Thesis, Queensland University of Technology, 2007. https://eprints.qut.edu.au/16704/1/Peter_Lewis_Thesis.pdf.

Full text
Abstract:
Intraaortic balloon counterpulsation (IABP) is the most widely used mechanical support in the assistance of a failing heart.1 Despite extensive research in this field no experimental or clinical studies have been undertaken to evaluate the most effective manner to wean IABP.2 The research reported in this thesis examines early recognition of cardiac decompensation and the management of IABP weaning. Conducted in three phases, the aim of this research programme was to determine the best manner by which to wean IABP. Phase 1 utilised a comparative descriptive design to examine IABP practice at a single cardiothoracic tertiary referral hospital. The majority of data collection was prospective, however, the required sample size saw inclusion of some retrospective data. This single centre data were than compared with an international registry to contrast IABP management and outcome. Phase 2 utilised a questionnaire survey to audit all Australasian intensive care units. Survey results were combined and statistically analysed to describe Australasian IABP management, weaning and outcome. Phase 3 utilised a quasi-experimental, one-group, posttest-only design to clinically validate a tool designed to monitor a patient's cardiac function - the 'cardiac decompensation tool'. Phase 1 saw data collected for 669 IABP insertions over an 11 year period at a single Australian hospital. This cohort was compared against the 38,606 patient dataset of The Benchmark Counterpulsation Outcomes Registry. Australian IABP practice saw later application of the device in a higher acuity patient. Australian practice demonstrated a prejudice toward intraoperative use (34.2% versus 16.6%; p=< 0.0001) and an aversion to catheter laboratory support (10.6% versus 19%; p=< 0.0001). Australian mortality while slightly higher, remained comparable (22% versus 20.8%; p=ns). Phase 2 response rate was 60%. The most common Australasian method of IABP support withdrawal was ratio reduction only (61%). Units with a documented weaning policy were less likely to require balloon reinsertion or pharmacologic escalation following IABP removal (p=0.06). Indicators most likely to demonstrate a patient's readiness for IABP weaning were blood pressure (92%), heart rate (76%) and wedge pressure (59%). Phase 3 revealed cardiac decompensation tool scores to increase immediately prior to a treatment escalation (p=0.022) and decrease immediately following this escalation in therapy (p=0.0096). There was also some indication of decreasing scores prior to treatment minimisation (p=0.005). Tool scores demonstrated a corresponding treatment fluctuation up to three hours prior to the treatment intervention. With Phase 1 and 2 revealing many aspects of IABP practice to vary, the need for some direction regarding weaning is evident. Timely recognition of cardiac decompensation during IABP weaning allows an opportunity for the earlier escalation of treatment and consequent provision of increased cardiac support. Application of the Phase 3 cardiac decompensation tool can only assist in ensuring the best manner by which to support IABP weaning.
APA, Harvard, Vancouver, ISO, and other styles
6

Lewis, Peter Andrew. "Identification of early cardiac decompensation and the management of intraaortic balloon counterpulsation weaning." Queensland University of Technology, 2007. http://eprints.qut.edu.au/16704/.

Full text
Abstract:
Intraaortic balloon counterpulsation (IABP) is the most widely used mechanical support in the assistance of a failing heart.1 Despite extensive research in this field no experimental or clinical studies have been undertaken to evaluate the most effective manner to wean IABP.2 The research reported in this thesis examines early recognition of cardiac decompensation and the management of IABP weaning. Conducted in three phases, the aim of this research programme was to determine the best manner by which to wean IABP. Phase 1 utilised a comparative descriptive design to examine IABP practice at a single cardiothoracic tertiary referral hospital. The majority of data collection was prospective, however, the required sample size saw inclusion of some retrospective data. This single centre data were than compared with an international registry to contrast IABP management and outcome. Phase 2 utilised a questionnaire survey to audit all Australasian intensive care units. Survey results were combined and statistically analysed to describe Australasian IABP management, weaning and outcome. Phase 3 utilised a quasi-experimental, one-group, posttest-only design to clinically validate a tool designed to monitor a patient's cardiac function - the 'cardiac decompensation tool'. Phase 1 saw data collected for 669 IABP insertions over an 11 year period at a single Australian hospital. This cohort was compared against the 38,606 patient dataset of The Benchmark Counterpulsation Outcomes Registry. Australian IABP practice saw later application of the device in a higher acuity patient. Australian practice demonstrated a prejudice toward intraoperative use (34.2% versus 16.6%; p=< 0.0001) and an aversion to catheter laboratory support (10.6% versus 19%; p=< 0.0001). Australian mortality while slightly higher, remained comparable (22% versus 20.8%; p=ns). Phase 2 response rate was 60%. The most common Australasian method of IABP support withdrawal was ratio reduction only (61%). Units with a documented weaning policy were less likely to require balloon reinsertion or pharmacologic escalation following IABP removal (p=0.06). Indicators most likely to demonstrate a patient's readiness for IABP weaning were blood pressure (92%), heart rate (76%) and wedge pressure (59%). Phase 3 revealed cardiac decompensation tool scores to increase immediately prior to a treatment escalation (p=0.022) and decrease immediately following this escalation in therapy (p=0.0096). There was also some indication of decreasing scores prior to treatment minimisation (p=0.005). Tool scores demonstrated a corresponding treatment fluctuation up to three hours prior to the treatment intervention. With Phase 1 and 2 revealing many aspects of IABP practice to vary, the need for some direction regarding weaning is evident. Timely recognition of cardiac decompensation during IABP weaning allows an opportunity for the earlier escalation of treatment and consequent provision of increased cardiac support. Application of the Phase 3 cardiac decompensation tool can only assist in ensuring the best manner by which to support IABP weaning.
APA, Harvard, Vancouver, ISO, and other styles
7

Mehta, Paresh Arvind. "The early high-risk period for patients with incident heart failure : a two-centre UK population-based study in Hillingdon and Hastings evaluating prognosis and mode of death." Thesis, Imperial College London, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.519586.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ganesh, Jagatheesan Sarvana. "The role of primary graft failure/dysfunction in the early mortality of heart and lung transplantation : a multi-centre perspective cohort study performed under the auspices of the UK Cardiothoracic Transplant Audit." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.590626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sánchez, Martínez Sergio. "Multi-feature machine learning analysis for an improved characterization of the cardiac mechanics." Doctoral thesis, Universitat Pompeu Fabra, 2018. http://hdl.handle.net/10803/663748.

Full text
Abstract:
This thesis focuses on the development of machine learning tools to better characterize the cardiac anatomy and function in the context of heart failure, and in particular their extension to consider multiple parameters that help identifying the pathophysiological aspects underlying disease. This advanced and personalized characterization may eventually allow assigning patients to clinically-meaningful phenogroups with a uniform treatment response and/or disease prognosis. Specifically, the thesis copes with the technical difficulties that multivariate analyses imply, paying special attention to properly combine different descriptors that might be of different nature (e.g., patterns, continuous, or categorical variables) and to reduce the complexity of large amounts of data up to a meaningful representation. To this end, we implemented an unsupervised dimensionality reduction technique (Multiple Kernel Learning), which highlights the main characteristics of complex, high-dimensional data into fewer dimensions. For our computational analysis to be useful for the clinical community, it should remain fully interpretable. We made special emphasis in allowing the user to be aware of how the input to the learning process models the obtained output, through the use of multi-scale kernel regression techniques among others.
Esta tesis se centra en el desarrollo de herramientas de aprendizaje automático para mejorar la caracterización de la anatomía y la función cardíaca en el contexto de insuficiencia cardíaca, y, en particular, su extensión para considerar múltiples parámetros que ayuden a identificar los aspectos pato-fisiológicos subyacentes a la enfermedad. Esta caracterización avanzada y personalizada podría en última instancia permitir asignar pacientes a fenogrupos clínicamente relevantes, que demuestren una respuesta uniforme a un determinado tratamiento, o un mismo pronóstico. Específicamente, esta tesis lidia con las dificultades técnicas que implican los análisis multi-variable, prestando especial atención a combinar de forma apropiada diferentes descriptores que pueden ser de diferente naturaleza (por ejemplo, patrones, o variables continuas o categóricas), y reducir la complejidad de grandes cantidades de datos mediante una representación significativa. Con este fin, implementamos una técnica no supervisada de reducción de dimensionalidad (Multiple Kernel Learning), que destaca las principales características de datos complejos y de alta dimensión utilizando un número reducido de dimensiones. Para que nuestro análisis computacional sea útil para la comunidad clínica debería ser enteramente interpretable. Por eso, hemos hecho especial hincapié en permitir que el usuario sea consciente de cómo los datos entrantes al algoritmo de aprendizaje modelan el resultado obtenido mediante el uso de técnicas de regresión kernel multi-escala, entre otras.
APA, Harvard, Vancouver, ISO, and other styles
10

Barbosa, Mário Augusto Rodrigues Teixeira 1980. "Predictors of early readmission in chronic heart failure : REFERENCE (pREdictors oF Early REadmission iN Chronic hEart failure)." Master's thesis, 2019. http://hdl.handle.net/10451/39451.

Full text
Abstract:
Tese de mestrado, Doenças Metabólicas e Comportamento Alimentar, Universidade de Lisboa, Faculdade de Medicina, 2019
The present thesis is based on the premise that chronic heart failure patients have a high morbidity and mortality due to the fact that cardiac insufficiency per se evolves inexorably, and that it affects an elder and frail population, suffering from multiple pathologies, polymedicated and even socio-economically vulnerable. The increase of life expectancy, inherent to the improvement of health care, determined a parallel augment of chronic heart failure patients. Albeit we have assisted to a consistent decline in the rate of heart failure hospitalizations, surprisingly, short-term readmission and mortality persist high, irrespective of clinical innovations and guideline directed management, representing a tremendous health care burden. It urges to define a short-term prognosis for these patients in order to reduce the readmission and premature mortality rates due to its socio-economic impact. The main purpose of this dissertation is to characterize at risk patients for early (defined as a period of 90 days post-discharge) readmission, due to heart failure, and overall death. The putative role of biochemical cardiovascular markers in clinical decision making, principally in recognizing high risk patients that could benefit from therapeutic intensification and stricter surveillance is also addressed. To characterize the population we addressed disease related risk factors [namely the etiology, the New York Heart Association Functional (NYHA) Class, left ventricular ejection fraction (LVEF), right ventricular function, signs and symptoms], non-modifiable cardiovascular risk factors, modifiable cardiovascular risk factors, comorbidities [chronic kidney disease (CKD), anemia, iron deficiency, thyroid function], therapeutic and biomarkers [specifically troponins, proBNP-Aminoterminal B-type Natriuretic Peptide (NT-proBNP), Galectin-3 (Gal-3), Suppression of Tumorigenicity 2 (ST2), Mid-Regional pro-Adrenomedullin (pro-ADM)] and Erythropoietin (EPO).
A presente tese baseia-se na premissa de que os doentes que padecem de insuficiência cardíaca crónica apresentam uma morbilidade e mortalidade elevadas fruto da evolução per se inexorável da insuficiência cardíaca e do facto de afetar uma população maioritariamente idosa, frágil, que sofre de múltiplas patologias, polimedicada e, inclusive, socioeconomicamente desprovida. O aumento da esperança de vida, inerente à melhoria dos cuidados de saúde, determinou um incremento paralelo da prevalência da insuficiência cardíaca crónica. Apesar de se ter assistido a um declínio das taxas de internamento por insuficiência cardíaca, surpreendentemente, as taxas de reinternamento e mortalidade precoces mantêm-se elevadas, independentemente dos avanços clínicos e abordagem em conformidade com as directrizes preconizadas, sobrecarregando tremendamente o sistema de saúde. Atendendo ao seu impacto socioeconómico urge definir o prognóstico a curto prazo destes doentes a fim de reduzir a taxa de readmissão e mortalidade precoces. Trata-se de um estudo de coorte prospetivo observacional, unicêntrico, com um único braço, de utilidade diagnóstica. O objetivo principal do estudo foi caracterizar os doentes de risco para readmissão e mortalidade precoces (definido como o período até 90 dias pós-alta) por insuficiência cardíaca. Apesar do propósito deste estudo ser, primeiramente, definir o prognóstico a curto prazo da insuficiência cardíaca, o seguimento prolongado permitiu-nos caracterizar, também, a mortalidade a longo prazo. Consideramos a mortalidade global atendendo a que a maioria dos doentes não faleceu no hospital, pelo que não tivemos acesso às certidões de óbito. O objetivo secundário foi avaliar a importância de biomarcadores emergentes no prognóstico da insuficiência cardíaca. Para caracterizar a população abordamos fatores de risco relacionados com a insuficiência cardíaca per se (nomeadamente a etiologia, a classe funcional da NYHA, a fração de ejecção do ventrículo esquerdo, a função do ventrículo direito, sinais e sintomas), fatores de risco cardiovasculares não-modificáveis, factores de risco cardiovasculares modificáveis, comorbilidades (tais como a doença renal crónica, a anemia, a deficiência de ferro, a função tiroideia), a terapêutica e biomarcadores (troponinas, NT-proBNP, galectina-3, ST2, pro-ADM e EPO).
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Early heart failure"

1

Don, Brown. Early-stage congestive heart failure. Seattle, WA: Natural Product Research Consultants, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Seth, Runjan. Inotropic and lusitropic response to gbs-adrenergic stimulation, hemodynamics, and metabolic parameters in early experimental heart failure. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Trongtō̜sak, Phētcharat. Phon rūamkan khō̜ng yātān bētā ʻǣtrīnœ̄čhik rīsēptœ̄ læ ʻǣngčhīʻōthēnsin rīsēptœ̄ tō̜ kāndamnœ̄n rōk raya rǣk nai phāwa hūačhai lomlēo =: Combined effects of ss-adrenergic blocker and angiotensin receptor blocker on the early progression of heart failure : rāingān kānwičhai. [Chonburi]: Mahāwitthayālai Būraphā, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dalzell, Jonathan R., Colette E. Jackson, Roy Gardner, and John JV McMurray. Acute heart failure: early pharmacological therapy. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0052.

Full text
Abstract:
Acute heart failure syndromes consist of a spectrum of clinical presentations due to an impairment of some aspect of the cardiac function. They represent a final common pathway for a vast array of pathologies and may be either a de novo presentation or, more commonly, a decompensation of pre-existing chronic heart failure. Despite being one of the most common medical presentations, there are no definitively proven prognosis-modifying treatments. The mainstay of current therapy is oxygen and intravenous diuretics. However, within this spectrum of presentations, there is a crucial dichotomy which governs the ultimate treatment approach, i.e. the presence, or absence, of cardiogenic shock. Patients without cardiogenic shock may receive vasodilators, whilst shocked patients should be considered for treatment with inotropic therapy or mechanical circulatory support, when appropriate and where available.
APA, Harvard, Vancouver, ISO, and other styles
5

Dalzell, Jonathan R., Colette E. Jackson, Roy Gardner, and John JV McMurray. Acute heart failure: early pharmacological therapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199687039.003.0052_update_001.

Full text
Abstract:
Acute heart failure syndromes consist of a spectrum of clinical presentations due to an impairment of some aspect of the cardiac function. They represent a final common pathway for a vast array of pathologies and may be either a de novo presentation or, more commonly, a decompensation of pre-existing chronic heart failure. Despite being one of the most common medical presentations, there are no definitively proven prognosis-modifying treatments. The mainstay of current therapy is oxygen and intravenous diuretics. However, within this spectrum of presentations, there is a crucial dichotomy which governs the ultimate treatment approach, i.e. the presence, or absence, of cardiogenic shock. Patients without cardiogenic shock may receive vasodilators, whilst shocked patients should be considered for treatment with inotropic therapy or mechanical circulatory support, when appropriate and where available.
APA, Harvard, Vancouver, ISO, and other styles
6

Tragante, Vinicius, Anna Pilbrow, and Katrina Poppe, eds. Improving Early Detection and Risk Prediction in Heart Failure. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-322-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burford, Judy. Early readmission in the elderly with congestive heart failure. 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vranckx, Pascal, Wilfried Mullens, and Johan Vijgen. Non-pharmacological therapy of acute heart failure: when drugs alone are not enough. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0053.

Full text
Abstract:
Acute heart failure syndrome has been defined as new-onset or a recurrence of worsening signs and symptoms of heart failure, necessitating urgent or emergency management. The management of acute heart failure syndrome is challenging, given the heterogeneity of the patient population, in terms of the clinical presentation, pathophysiology, prognosis, and therapeutic options. The management of acute heart failure syndrome is a dynamic process, requiring ongoing simultaneous diagnosis (monitoring) and treatment. Pharmacological agents remain the mainstay of therapy for acute heart failure syndrome. However, at all time, during the early diagnostic, aetiologic, and therapeutic work-up, non-pharmacologic therapy may be indicated and should be considered. The management of the complex cardiac patient with acute heart failure syndrome and/or (potential) haemodynamic compromise has become a special dimension for specialized myocardial intervention centres, providing 24 hours per day and 7 days per week state-of-the-art facilities for (primary) percutaneous coronary intervention and cardiac intensive care, including mechanical ventilation, ultrafiltration, with or without dialysis, and short-term percutaneous mechanical circulatory support. Through the understanding of the underlying pathophysiology and approaches into the problems of acute heart failure syndrome, one should be better prepared to understand and treat its many facets.
APA, Harvard, Vancouver, ISO, and other styles
9

Plebani, Mario, Monica Maria Mion, and Martina Zaninotto. Biomarkers of renal and hepatic failure. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0039.

Full text
Abstract:
In the last few years, major advances have been achieved in the understanding of the molecular and pathophysiological mechanisms which underlie the complex interactions between the heart and the kidney, as well as between the heart and the liver. According to these new insights, new biomarkers have been proposed for better evaluating and monitoring patients affected by cardiovascular diseases. In addition, some biomarkers should be used as risk factors and for an early identification and treatment of these severe diseases. This chapter reviews the most important biomarkers for evaluating the ‘cardiorenal syndrome’, in particular, the measurement of serum creatinine and its use for calculating the glomerular filtration rate which, with the new and more efficient equation, namely Chronic Kidney Disease Epidemiology Collaboration, still remains the most widely used biomarker. The role of newer biomarkers will be explored. The measurement of cystatin C, representing additional information, particularly in paediatric age groups and in the early phase of kidney disease, plays an increasing role. Neutrophil gelatinase-associated lipocalin is a recently developed and very promising new biomarker for the diagnosis of acute kidney injury, while the well-known albumin/creatinine ratio has been re-evaluated as a simple and useful tool for an early identification of kidney disease. Regarding liver diseases, a growing body of evidence demonstrates the usefulness of non-invasive makers of hepatic fibrosis that may avoid the need for a liver biopsy in most patients. A promising field of research is represented by the role of non-alcoholic fatty liver disease in the pathogenesis of cardiovascular disease.
APA, Harvard, Vancouver, ISO, and other styles
10

Fye, W. Bruce. President Roosevelt’s Secret Hypertensive Heart Disease. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199982356.003.0007.

Full text
Abstract:
Franklin D. Roosevelt’s health was a factor in the 1944 election. Presidential press secretary Stephen Early and White House physician Ross McIntire worried that Thomas Dewey might win if voters learned that Roosevelt had severe hypertension and had an episode of congestive heart failure. Three weeks before the election, Mayo cardiologist Arlie Barnes visited the Bethesda Naval Medical Center where he learned that some physicians suspected that Roosevelt had a “serious heart ailment.” When Barnes returned to Rochester he mentioned this to a few friends. Word of this conversation reached Early, and FBI agents interrogated Barnes and other Mayo physicians two weeks before the election. During the campaign’s closing days, White House insiders orchestrated events designed to showcase a healthy commander in chief. Stifling rumors about Roosevelt’s health was part of their strategy to defeat Dewey. Less than three months into his fourth term, Roosevelt had a stroke and died.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Early heart failure"

1

Eberle, Balthasar, and Heiko Kaiser. "Early Postoperative Management." In Heart Failure, 205–22. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-98184-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rush, Janet E., and Mariell Jessup. "Drugs for Heart Failure." In Early Phase Drug Evaluation in Man, 313–25. London: Macmillan Education UK, 1990. http://dx.doi.org/10.1007/978-1-349-10705-6_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Qureshi, Waqas Tariq, Javed Butler, Sean P. Collins, Alec J. Moorman, and Mihai Gheorghiade. "Early Medical Management of Hospitalization for Heart Failure (HHF)." In Management of Heart Failure, 113–49. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-6657-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Spratt, John R., Ziad Taimeh, Thenappan Thenappan, and Ranjit John. "Adult Orthotopic Heart Transplantation: Early Complications." In Congestive Heart Failure and Cardiac Transplantation, 493–504. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-44577-9_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jurmann, Michael J., Axel Haverich, Hans-Joachim Schaefers, Thorsten Wahlers, Jochen Cremer, and Hans Georg Borst. "Early graft failure after heart transplantation: Circulatory assist versus retransplantation." In Artificial Heart 3, 275–84. Tokyo: Springer Japan, 1991. http://dx.doi.org/10.1007/978-4-431-68126-7_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vassanelli, C., G. Morando, G. Menegatti, M. Turri, L. Zanolla, G. Besa, and P. Zardini. "Left Ventricular Aneurysmectomy and Ventriculoplasty: Early Angiographic Results and Long-Term Follow-Up." In Heart Failure Mechanisms and Management, 434–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-58231-8_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jansen, Piet, Christian Latrémouille, and Alain Carpentier. "Early Experience with the CARMAT Bioprosthetic Artificial Heart." In Mechanical Circulatory Support in End-Stage Heart Failure, 581–88. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43383-7_55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Scherillo, M., F. Scotto di Uccio, F. Vigorito, D. Miceli, M. G. Tesorio, V. Monda, and R. Calabrò. "Non-Invasive Evaluation and Early Treatment of Heart Failure Patients." In New Advances in Heart Failure and Atrial Fibrillation, 101–16. Milano: Springer Milan, 2003. http://dx.doi.org/10.1007/978-88-470-2087-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Alom, Zulfikar, Mohammad Abdul Azim, Zeyar Aung, Matloob Khushi, Josip Car, and Mohammad Ali Moni. "Early Stage Detection of Heart Failure Using Machine Learning Techniques." In Lecture Notes on Data Engineering and Communications Technologies, 75–88. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-6636-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Eid, Jad, Georges Badr, Amir Hajjam El Hassani, and Emmanuel Andres. "Heart Failure Occurrence: Mining Significant Patterns and 10 Days Early Prediction." In Emerging Technologies in Biomedical Engineering and Sustainable TeleMedicine, 101–12. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-14647-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Early heart failure"

1

Al-Mannai, Rashid Ebrahim, Mohammed Hamad Almerekhi, Mohammed Abdulla Al-Mannai, Mishahira N, Kishor Kumar Sadasivuni, Huseyin Cagatay Yalcin, Hassen M. Ouakad, Issam Bahadur, Somaya Al-Maadeed, and Asiya Albusaidi. "Artificial Intelligence in Predicting Heart Failure." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0130.

Full text
Abstract:
Heart Failure is a major chronic disease that is increasing day by day and a great health burden in health care systems world wide. Artificial intelligence (AI) techniques such as machine learning (ML), deep learning (DL), and cognitive computer can play a critical role in the early detection and diagnosis of Heart Failure Detection, as well as outcome prediction and prognosis evaluation. The availability of large datasets from difference sources can be leveraged to build machine learning models that can empower clinicians by providing early warnings and insightful information on the underlying conditions of the patients
APA, Harvard, Vancouver, ISO, and other styles
2

Zamani, A., S. Ahdi Rezaeieh, and A. M. Abbosh. "Frequency domain method for early stage detection of congestive heart failure." In 2014 IEEE MTT-S International Microwave Workshop Series on RF and Wireless Technologies for Biomedical and Healthcare Applications (IMWS-BIO). IEEE, 2014. http://dx.doi.org/10.1109/imws-bio.2014.7032455.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nugraha, Krishna, M. Fadlan, Dea Kurniawan, Liemena Adrian, Faris Nugroho, Puspa Lestari, Seprian Widasmara, Anita Santoso, and Mohammad Rohman. "The Symptoms-based Algorithm for Early Detection of Systolic Heart Failure." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009388300380041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yang-Hyun, CHO. "7 Early experience with implantable LVAD at samsung medical centre, seoul." In 1st Asia Pacific Advanced Heart Failure Forum (APAHFF), 15th December 2017, Hong Kong. BMJ Publishing Group Ltd, British Cardiovascular Society and Asia Pacific Heart Association, 2018. http://dx.doi.org/10.1136/heartasia-2018-apahff.7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Candelieri, A., D. Conforti, A. Sciacqua, and F. Perticone. "Knowledge Discovery Approaches for Early Detection of Decompensation Conditions in Heart Failure Patients." In 2009 Ninth International Conference on Intelligent Systems Design and Applications. IEEE, 2009. http://dx.doi.org/10.1109/isda.2009.204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dogu, Semih, Egemen Bilgin, Sulayman Joof, and Mehmet Nuri Akinci. "Feasibility of Distorted Born Iterative Method for Detecting Early Stage of Heart Failure." In 2020 IEEE MTT-S International Microwave Biomedical Conference (IMBioC). IEEE, 2020. http://dx.doi.org/10.1109/imbioc47321.2020.9385045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Butt, Muhammad Owais, Attique Ur Rehman, Sabeen Javaid, Tahir Muhammad Ali, and Ali Nawaz. "An Application of Artificial Intelligence for an Early and Effective Prediction of Heart Failure." In 2022 Third International Conference on Latest trends in Electrical Engineering and Computing Technologies (INTELLECT). IEEE, 2022. http://dx.doi.org/10.1109/intellect55495.2022.9969182.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Joe, Sadia Quadri, Luca Pollonini, Sharan Naribole, Jennifer Ding, Zongjun Zheng, Edward W. Knightly, and Clifford C. Dacso. "Blue scale: Early detection of impending congestive heart failure events via wireless daily self-monitoring." In 2014 Health Innovations and POCT. IEEE, 2014. http://dx.doi.org/10.1109/hic.2014.7038875.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Candelieri, A., D. Conforti, F. Perticone, A. Sciacqua, K. Kawecka-Jaszcz, and K. Styczkiewicz. "Early detection of decompensation conditions in heart failure patients by knowledge discovery: The HEARTFAID approaches." In 2008 35th Annual Computers in Cardiology Conference. IEEE, 2008. http://dx.doi.org/10.1109/cic.2008.4749186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kaiser, Alexander, Carissa Pocock, Pratibha Sharma, Nickolas Browdues, Kimberly Newman, and Frank Barnes. "Towards a method for early detection of congestive heart failure with an electrocardiogram and acoustic transducers." In 2012 IEEE Signal Processing in Medicine and Biology Symposium (SPMB). IEEE, 2012. http://dx.doi.org/10.1109/spmb.2012.6469460.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Early heart failure' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography